CD4 and melanoma: After using these constructs to treat pre-established melanomas in animal models, remission was observed, which is associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4+ interleukin (IL)-17 dependent response (Pulido et al., 2012).